Key facts
- Cuize Medicine’s last known valuation is $83.4M (Jun 2025).
- It has raised $12.6M; the latest was Later Stage VC ($4.6M) in Jun 2025.
- Notable investors include Goldport Capital, Jiangguo Investment Management, Zhejiang Xianju Pharmaceutical Company.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cuize Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Cuize Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cuize Medicine
Developer of pulmonary therapy medication intended to be used for the perioperative period. The company developed a sustained release technology platform and inhalation powder technology platform, enabling to reduce side effects and delivers sustained curative effects without burst release phenomenon to pulmonary patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Ownership
- Privately Held (backing)
Cuize Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cuize Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cuize Medicine in its N-PORT filings yet. We sweep new filings monthly.